Last updated 2026-06-18
- Went public, Jun 2020
- Raised $26.7M PIPE, Jun 2025
- Raised $50M Series E, Sep 2019
Total raised
$239.2M
Last: B Round 2025-08
Stage
Public
Founded
2008
Headcount
68
HQ
Petah Tikva, Israel
Sector
Health Tech & Life Sciences
About
PolyPid is a late-stage biopharmaceutical company focused on improving surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with active pharmaceutical ingredients to enable the precise delivery of drugs at optimal release rates over durations ranging from days to months.
PolyPid’s lead product candidate, D-PLEX100, is in a phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the company’s OncoPLEX is currently in preclinical stage testing for the treatment of solid tumors, beginning with glioblastomas.
Funding history · 13 rounds · $239.2M total
2025-08
B Round
Undisclosed
2025-06
PIPE
$26.7M
2024-12
PIPE
$14.5M
2024-08
PIPE
$8.1M
2024-01
PIPE
$16.2M
2022-04
Debt Financing
$12.5M
2019-09
E Round
$50.0M
2018-11
E Round
$15.0M
2016-11
Debt Financing
$5.3M
2016-02
C Round
$8.1M
2016-02
D Round
$22.0M
2012-01
B Round
$2.0M
2010-01
A Round
$1.4M
Q&A
- What is PolyPid's primary focus as a biopharmaceutical company?
- PolyPid is a late-stage biopharmaceutical company focused on improving surgical outcomes through locally administered, controlled, prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology.
- What is the current status of PolyPid's lead product candidate, D-PLEX100?
- PolyPid's lead product candidate, D-PLEX100, is currently in a phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections.
- When did PolyPid go public and on which stock exchange?
- PolyPid went public on NASDAQ in June 2020 through an Initial Public Offering that raised $69,000,000.
- What is the status of PolyPid's OncoPLEX product?
- PolyPid's OncoPLEX is currently in preclinical stage testing for the treatment of solid tumors, beginning with glioblastomas.
- What was PolyPid's most recent PIPE funding round with disclosed investors?
- In January 2024, PolyPid completed a PIPE funding round, raising $16,200,000, with participation from Rosalind Advisors.
- Which investor participated in PolyPid's Debt Financing round in April 2022?
- Kreos Capital participated in PolyPid's Debt Financing round in April 2022, which raised $12,500,000.
- Who is the current CEO of PolyPid?
- Dikla Czaczkes Akselbrad is the CEO of PolyPid.
Team · 5
CFO
Chief Commercial Officer
Chief Operating Officer - US
Executive Vice President R&D, Clinical and Regulatory Affairs
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2CB2B2C
Highlights
1 PatentsVerified
Tags
orthopedicsdentaldrug-deliverypharma-companiessustained-releasetherapeuticspain-reliefcancerbiopharmaceuticalsurgeons
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | polypid.com |
|---|---|
| linkedin.com/company/3835371 | |
| YouTube | youtube.com/channel/UCg4GYf435RD4QyLQUuhJc7g |
Identifiers & details
| Founded | 2008-2 |
|---|---|
| Employees (exact) | 68 |
| Market cap | $72.2M |
| Status reason | Public on NASDAQ on Jun 2020; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2023-03 | $6.2M | |||
| 2020-06 | $69.0M |